Bronchodilator Efficacy of a Single-Dose 12/400- µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair ® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial

ConclusionsOur findings revealed significant changes from baseline in post-bronchodilator peak and average FEV1 and forced vital capacity responses, indicating bronchodilator efficacy of a single-dose 12/400  µg formoterol plus budesonide dry powder formulation delivered by Discair® in patients with chronic obstructive pulmonary disease.Trial RegistrationClinicalTrials.gov Identifier NCT03028701.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research